Cardiovascular disease and COVID-19

Manish Bansal, Manish Bansal

Abstract

Background and aims: Many patients with coronavirus disease 2019 (COVID-19) have underlying cardiovascular (CV) disease or develop acute cardiac injury during the course of the illness. Adequate understanding of the interplay between COVID-19 and CV disease is required for optimum management of these patients.

Methods: A literature search was done using PubMed and Google search engines to prepare a narrative review on this topic.

Results: Respiratory illness is the dominant clinical manifestation of COVID-19; CV involvement occurs much less commonly. Acute cardiac injury, defined as significant elevation of cardiac troponins, is the most commonly reported cardiac abnormality in COVID-19. It occurs in approximately 8-12% of all patients. Direct myocardial injury due to viral involvement of cardiomyocytes and the effect of systemic inflammation appear to be the most common mechanisms responsible for cardiac injury. The information about other CV manifestations in COVID-19 is very limited at present. Nonetheless, it has been consistently shown that the presence of pre-existing CV disease and/or development of acute cardiac injury are associated with significantly worse outcome in these patients.

Conclusions: Most of the current reports on COVID-19 have only briefly described CV manifestations in these patients. Given the enormous burden posed by this illness and the significant adverse prognostic impact of cardiac involvement, further research is required to understand the incidence, mechanisms, clinical presentation and outcomes of various CV manifestations in COVID-19 patients.

Keywords: Arrhythmia; COVID-19; Cardiac troponins; Cardiogenic shock; Coronavirus disease 2019; Heart failure; Myocardial infarction; Myocarditis; SARS-CoV-2.

Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.

References

    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease Control and prevention. J Am Med Assoc. 2020
    1. The world health organization coronavirus disease 2019 (COVID-19) situation report –61. Available at:
    1. Xiong T.Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020
    1. Li B., Yang J., Zhao F. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020
    1. Zhou F., Yu T., Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020
    1. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Chen D., Li X., song q, Hu C., Su F., Dai J. Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19) medRxiv. 2020 doi: 10.1101/2020.02.27.20028530.
    1. Wang D., Hu B., Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. 2020
    1. Arentz M., Yim E., Klaff L. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington state. J Am Med Assoc. 2020
    1. Lippi G., Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020
    1. Oudit G.Y., Kassiri Z., Jiang C. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39:618–625.
    1. Wu Q., Zhou L., Sun X. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 2017;7:9110.
    1. Corrales-Medina V.F., Alvarez K.N., Weissfeld L.A. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. J Am Med Assoc. 2015;313:264–274.
    1. Tam C.F., Cheung K.S., Lam S. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020 CIRCOUTCOMES120006631.
    1. ACC clinical bulletin focuses on cardiac implications of coronavirus (COVID-19) Available at:
    1. ASE statement on COVID-19. Available at:
    1. Ferrario C.M., Jessup J., Chappell M.C. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605–2610.
    1. HFSA/ACC/AHA statement addresses concerns Re: using RAAS antagonists in COVID-19. Available at:
    1. Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers. Available at:
    1. Information for clinicians on therapeutic options for COVID-19 patients. Available at:

Source: PubMed

3
S'abonner